Zealand Pharma A/S

Headquarters: Copenhagen, Denmark

Employees: 355

CEO: Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA

show_chart OMXC: ZEAL +1.65%

Market Cap

kr.11.00 Billion

DKK as of Jan. 1, 2023

US$1.58 Billion

history Market Cap History

Zealand Pharma A/S market capitalization over time

Evolution of Zealand Pharma A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Zealand Pharma A/S

Detailed Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Stocks & Indices

Zealand Pharma A/S has the following listings and related stock indices.



Stock: FSX: 22Z

Stock: FSX: 22ZA




Sydmarken 11


Copenhagen, 2860


Phone: 45 88 77 36 00

Fax: 45 88 77 38 98